Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance
BackgroundVedolizumab is a gut-selective biologic widely used for inflammatory bowel disease (IBD). While randomized controlled trials (RCTs) provide initial safety profiles, real-world pharmacovigilance data are crucial for identifying a broader spectrum of adverse events (AEs), including rare or u...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-01-01
|
| Collection: | Frontiers in Pharmacology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1700820/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|